CRSP - Crispr Therapeutics AG
Crispr Therapeutics AG Logo

CRSP - Crispr Therapeutics AG

https://www.crisprtx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.

52W High
$71.13
52W Low
$30.04
MA Status:
50D: Below 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.81
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
23.36
EV/EBITDA (<8 favorable)
14.16
EV/Revenue (<3 favorable)
99.54
P/S (TTM) (<3 favorable)
131.13
P/B (<3 favorable)
2.92
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.64%
Institutions (25–75% balanced)
80.91%
Shares Outstanding
90,950,000
Float
90,501,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
38,050,000
Gross Profit (TTM)
-382,457,984
EPS (TTM)
-5.40
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-149.18%
ROE (TTM) (>15% strong)
-0.25%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.73
Momentum
Bearish momentum
Value
-1.0074
Previous
-1.2487
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025